Promising Alzheimer’s Therapies ANAVEX 2-73, ANAVEX PLUS Approved For Phase 2 Trials
Anavex Life Sciences Corp. will initiate a Phase 2a clinical trial for the treatment of Alzheimer’s disease with their compounds – ANAVEX 2-73 and ANAVEX PLUS – after receiving regulatory approval by the Ethics Committee in Australia. ANAVEX 2-73, an orally available drug candidate, is under investigation to treat…